CRWV vs LLY: Which Is the Better Buy?
Side-by-side comparison of CoreWeave, Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
CoreWeave, Inc. · Technology
$89.89
+24.6% upside to fair value
Med Conviction
Grade C+
VS
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWV |
LLY |
| Current Price |
$89.89 |
$1,179.09 |
| Fair Value Estimate |
$112.00 |
$1,552.32 |
| Upside to Fair Value |
+24.6%
|
+31.7%
|
| Market Cap |
$49.0B |
$1,110.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.6x
|
34.3x
|
| Price / Sales |
7.9x
|
14.6x
|
| Price / FCF |
—
|
77.7x
|
| Revenue Growth YoY |
+111.6%
|
+55.5%
|
| Gross Margin |
69.4%
|
83.5%
|
| Operating Margin |
-2.6%
|
45.9%
|
| Return on Equity |
-33.5%
|
101.3%
|
| Dividend Yield |
0% |
0.55% |
| FCF Yield |
-21.6%
|
1.29%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
CoreWeave is the leading neocloud, a GPU-specialized cloud infrastructure provider built to serve the compute-hungry demands of generative AI training and inference. Since its March 2025 IPO, revenue has scaled roughly 112% year over year to $2.08 billion in the first quarter of 2026, backed by a $99.4 billion contracted revenue backlog and marquee agreements with Microsoft, OpenAI, Meta, Anthrop…
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Accumulation Zones
| Metric |
CRWV |
LLY |
| Zone Low |
$84.00 |
$1,164.24 |
| Zone High |
$95.00 |
$1,319.47 |
| In Buy Zone? |
Yes
|
Yes
|